All‐cause mortality · people with fulminant hepatic failure secondary to paracetamol (acetaminophen) overdose
Intravenous acetylcysteine may leads to lower mortality compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortality · people with paracetamol (acetaminophen) overdose
1 finding from 1 review
Hepatotoxicity · people with paracetamol (acetaminophen) overdose
Methionine and supportive treatment may leads to lower hepatotoxicity compared with supportive treatment (low certainty).
1 finding from 1 review
Hepatotoxicity · people with paracetamol (acetaminophen) overdose
It is very uncertain whether initial infusion rate of intravenous acetylcysteine over 15 minutes changes hepatotoxicity compared with 60 minutes (very low certainty).
1 finding from 1 review
Any adverse event · people with paracetamol (acetaminophen) overdose
Initial infusion rate of intravenous acetylcysteine over 15 minutes may leads to lower any adverse event compared with 60 minutes (low certainty).
1 finding from 1 review
All‐cause mortality · people with paracetamol (acetaminophen) overdose
1 finding from 1 review
Hepatotoxicity · people with paracetamol (acetaminophen) overdose
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · people with paracetamol (acetaminophen) overdose
It is very uncertain whether charcoal haemoperfusion changes mortality compared with no intervention (very low certainty).
1 finding from 1 review
All‐cause mortality · people with paracetamol (acetaminophen) overdose
It is very uncertain whether cysteamine changes mortality compared with no intervention (very low certainty).
1 finding from 1 review
Hepatotoxicity (aspartate aminotransferase > 1000 IU/L) · people with paracetamol (acetaminophen) overdose
Cysteamine may leads to lower hepatotoxicity (aspartate aminotransferase > 1000 IU/L) compared with no intervention (low certainty).
1 finding from 1 review
All‐cause mortality · people with paracetamol (acetaminophen) overdose
It is very uncertain whether cysteamine changes mortality compared with dimercaprol (very low certainty).
1 finding from 1 review
Mean maximum alanine aminotransferase (IU/L) · people with paracetamol (acetaminophen) overdose
1 finding from 1 review
All‐cause mortality · people with paracetamol (acetaminophen) overdose
1 finding from 1 review
Hepatotoxicity (aspartate aminotransferase > 1000 IU/L) · people with paracetamol (acetaminophen) overdose
It is very uncertain whether cysteamine changes hepatotoxicity (aspartate aminotransferase > 1000 U/L) compared with methionine (randomised trials) (very low certainty).
1 finding from 1 review
All‐cause mortality · people with paracetamol (acetaminophen) overdose
1 finding from 1 review
Outcomes** · liver transplanted patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · liver transplanted patients
Glucocorticosteroid avoidance or withdrawal showed no clear difference in all‐cause mortality compared with glucocorticosteroid‐based immunosuppression (low certainty).
1 finding from 1 review
Graft loss including death · liver transplanted patients
Glucocorticosteroid avoidance or withdrawal showed no clear difference in graft loss including death compared with glucocorticosteroid‐based immunosuppression (low certainty).
1 finding from 1 review
Acute rejection · liver transplanted patients
Glucocorticosteroid avoidance or withdrawal may leads to higher acute rejection compared with glucocorticosteroid‐based immunosuppression (low certainty).
1 finding from 1 review
Infection · liver transplanted patients
It is very uncertain whether glucocorticosteroid avoidance or withdrawal changes infection compared with glucocorticosteroid‐based immunosuppression (very low certainty).
1 finding from 1 review